Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy.
BACKGROUND
Monitoring the response to immunotherapy entails understanding exposure to relevant allergens. For the major indoor allergens, this requires sampling of dust from the patient's house. The objectives of this study were to measure indoor allergen levels during a controlled trial of dust mite immunotherapy for asthma and to relate these results to serum antibody levels.


METHODS
Eighty-eight asthmatic patients with mite allergy from seven geographic areas in the United States were enrolled in and completed a course of immunotherapy with Dermatophagoides extract or placebo control. Sensitization was evaluated by quantitative measurements of IgG and IgE antibodies. Dust samples were assayed for group I mite (Der p 1 and Der f 1), cat (Fel d 1), and cockroach (Bla g 1) allergens by monoclonal antibody-based ELISA.


RESULTS
Over the 4 years of the study, each of the houses had at least one sample that contained more than 2 micrograms of group I mite allergen per gram of dust. Mean mite allergen levels, however, varied over a wide range, from 0.2 microgram/gm or less to more than 50 micrograms/gm. IgE antibodies to mite were present in sera from 78% of the patients, whereas IgE antibodies to cat and cockroach allergens were found in sera from 34% and 11% of patients, respectively. Sixty-four percent of the patients had exposure and sensitization to mite, whereas the comparable figure for each of the other allergens was 5%.


CONCLUSIONS
Examination of the results suggested that allergen exposure, relative to a trial of immunotherapy, could be expressed as (1) the maximum level found in the house, (2) the percentage of sites having greater than 2 micrograms/gm, or (3) the mean value at the site with the maximum level. This report provides a background for evaluating the clinical results of immunotherapy in these patients and a model for the way in which sensitization and exposure should be monitored in studies of this kind.
Rose
G
G
Division of Allergy and Clinical Immunology, University of Virginia Medical Center, Charlottesville 22908, USA.
Arlian
L
L
Bernstein
D
D
Grant
A
A
Lopez
M
M
Metzger
J
J
Wasserman
S
S
Platts-Mills
T A
TA
D000293:Adolescent; D000328:Adult; D016902:Air Pollution, Indoor / Q000009:adverse effects; D000818:Animals; D000918:Antibody Specificity; D039741:Antigens, Dermatophagoides; D001249:Asthma / Q000276:immunology* / Q000628:therapy*; D002415:Cats; D004391:Dust / Q000009:adverse effects*; D005260:Female; D006023:Glycoproteins / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007073:Immunoglobulin E / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D008925:Mites / Q000276:immunology*; D012882:Skin Tests
D039741:Antigens, Dermatophagoides; D004391:Dust; D006023:Glycoproteins; D007074:Immunoglobulin G; D007073:Immunoglobulin E